Clinical trials: Metastatic Non-Small-Cell Lung Cancer
Non Small Cell Lung Cancer, Breast Cancer
A Study of YL202 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer and Breast Cancer
This is a phase 1, multicenter, open-label, first-in-human study of YL202 conducted in the United States and China. The study will evaluate the safety and tolerability of YL202 in patients with locally advanced or metastatic…
- Trial name
- NCT05653752
- Testing
- YL202
- Where
- 13 sites in United States, China
- Volunteers
- 80 people
- Sponsor
- MediLink Therapeutics (Suzhou) Co., Ltd.
Non Small Cell Lung Cancer (NSCLC)
A Study to Evaluate Safety and Efficacy of WSD0922-FU Combo With Osimertinib for NSCLC
This is a Phase I/II, Open Label Study of WSD0922-FU in Combination with Osimertinib for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer whose disease has progressed with third-generation EGFR-TKI with…
- Trial name
- WAYWIN103 (NCT07206498)
- Testing
- Osimertinib (Tagrisso®), WSD0922-FU
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Wayshine Biopharm, Inc.
Advanced Malignancies, Metastatic Cancer
INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies
The purpose of this study is to determine the safety, tolerability, and efficacy of INCAGN01876 when given in combination with immune therapies.
- Trial name
- NCT03277352
- Testing
- INCAGN01876, Epacadostat, Pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Incyte Biosciences International Sàrl
Positron-Emission Tomography, Immunomodulation
⁸⁹Zr-Df-IAB22M2C PET/CT in Patients With Selected Solid Malignancies or Hodgkin's Lymphoma
To determine the safety and feasibility of 89Zr-Df-IAB22M2C as an immunoPET tracer; determine the best time window and protein dose for imaging; determine the pharmacokinetic (PK) and biodistribution of the probe; and to…
- Conditions
- Positron-Emission Tomography, Immunomodulation, Metastatic Solid Malignancies, Hodgkin Lymphoma
- Trial name
- NCT03107663
- Testing
- ⁸⁹Zr-Df-IAB22M2C Infusion
- Where
- 3 sites in United States
- Volunteers
- 15 people
- Sponsor
- ImaginAb, Inc.
Solid Tumor, NSCLC
D-0316 in Patients With EGFR Positive Non Small Cell Lung Cancer
A Phase II, Open Label, Single-arm Study to Assess the Safety and Efficacy of D-0316 in Patients with Locally Advanced/Metastatic Non Small Cell Lung Cancer whose Disease has Progressed with Previous Epidermal Growth Factor…
- Conditions
- Solid Tumor, NSCLC, EGFR T790M
- Trial name
- NCT03861156
- Testing
- D-0316
- Where
- China
- Volunteers
- 290 people
- Sponsor
- InventisBio Co., Ltd
Non Small Cell Lung Cancer (NSCLC)
Osimertinib Study in Indian Patients
This is a prospective, single-arm, multicenter, phase-IV study investigating the safety of osimertinib in Indian adult patients.
- Trial name
- NCT03853551
- Testing
- Osimertinib
- Where
- 7 sites in India
- Volunteers
- 60 people
- Sponsor
- AstraZeneca
Locally Advanced or Metastatic NSCLC
ASKC202 Combined With Limertinib Versus Platinum-based Chemotherapy in Treatment of Locally Advanced or Metastatic NSCLC With MET Amplification/Overexpression After Failure of EGFR-TKI Therapy
This study is designed to compare the safety and efficacy of ASKC202 combined with Limertinib Versus platinum-based chemotherapy in locally advanced or metastatic NSCLC With MET Amplification/Overexpression after disease…
- Trial name
- NCT07109531
- Testing
- ASKC202+ Limertinib, Pemetrexed + Cisplatin /Carboplatin
- Where
- China
- Volunteers
- 286 people
- Sponsor
- Jiangsu Aosaikang Pharmaceutical Co., Ltd.
Locally Advanced or Metastatic Malignant Solid Tumors
A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors
Specific proteins found in tumors help the tumors spread and grow. People with solid tumors often have a protein called TROP2 in their tumor.
- Trial name
- NCT07287995
- Testing
- ASP2998, Pembrolizumab, Enfortumab Vedotin
- Where
- 9 sites in United States, Japan
- Volunteers
- 428 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Non-small Cell Lung Cancer
A Study Comparing the Efficacy and Safety Between IBI308 and Docetaxel in Patients With Advanced or Metastatic NSCLC
Clinical trial results demonstrate that anti-PD-1 antibodies prolonged OS to approximately 9 months compared with 6 months in docetaxel group.
- Trial name
- NCT03150875
- Testing
- IBI308, Docetaxel
- Where
- 2 sites in China
- Volunteers
- 290 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
NSCLC, EGFR Activating Mutation
Study of TY-9591 in Patients With a Lung Cancer With Brain or Leptomeningeal Metastases With EGFR Mutation
To evaluate the efficacy and safety of TY-9591 tablets in the treatment of EGFR mutation-positive non-small cell lung cancer (NSCLC) patients with brain or leptomeningeal metastases.
- Conditions
- NSCLC, EGFR Activating Mutation, Brain Metastases, Leptomeningeal Metastasis
- Trial name
- NCT05146219
- Testing
- TY-9591 Tablets
- Where
- China
- Volunteers
- 29 people
- Sponsor
- TYK Medicines, Inc
Nonsquamous Nonsmall Cell Neoplasm of Lung
Evaluate the Safety and Efficacy of BLEX 404 Oral Liquid Combined With Pemetrexed + Cisplatin Therapy
Maitake is reported with immunomodulatory functions against tumor growth in terms of its unique molecular structure, β-glucan polysaccharides within 1, 6 main chain having 1, 3 branches and a 1, 3 main chain having 1, 6 branches…
- Trial name
- NCT05764928
- Testing
- BLEX 404
- Where
- Taiwan
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Rgene Corporation
Non-Small Cell Lung Cancer
A Study of Linifanib (ABT-869) in Combination With Carboplatin/Paclitaxel in Japanese Subjects With Non-Small Cell Lung Cancer (NSCLC)
The primary objective of this study is to assess the safety and pharmacokinetics of linifanib, and identify tolerable dose of linifanib (ABT-869) in combination with carboplatin and paclitaxel in Japanese subjects with advanced…
- Trial name
- NCT01225302
- Testing
- Linifanib, Carboplatin, Paclitaxel
- Volunteers
- 12 people
- Sponsor
- AbbVie
NSCLC Stage IIIB, NSCLC Stage IV
Phase I Study of SPH1188-11 in NSCLC
This study will treat patients with advanced NSCLC who have already received at least one course of specific anti-cancer treatment but the tumour has started to re-grow following that treatment.
- Trial name
- SPH1188-11 (NCT03231475)
- Testing
- SPH1188-11
- Where
- China
- Sponsor
- Shanghai Pharmaceuticals Holding Co., Ltd
Non Small Cell Lung Cancer Stage IIIB
A Study of BIO-11006 in the Treatment of Advanced Non-Small Cell Lung Cancer
This Phase 2 is a randomized study in advanced Non-Small Cell lung cancer patients to evaluate safety and efficacy of aerosolized BIO-11006 in conjunction with chemotherapy.
- Trial name
- NCT03472053
- Testing
- BIO-11006 plus standard of care, Standard of Care
- Where
- 11 sites in India
- Volunteers
- 60 people
- Sponsor
- BioMarck Pharmaceuticals, Ltd.
Brain Metastasis, Non-small Cell Lung Cancer
Study of Patupilone in Patients With Brain Metastasis From Non-small Cell Lung Cancer
The study objective is to evaluate the safety and efficacy of patupilone with respect to early progression and response of patients with non-small cell lung cancer (NSCLC) metastatic to the brain, who have progressed after…
- Trial name
- NCT00219297
- Testing
- Patupilone
- Where
- 12 sites in United States
- Volunteers
- 50 people
- Sponsor
- Novartis Pharmaceuticals
Non-small Cell Lung Cancer
A Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With First Line Metastatic Squamous Non-small Cell Lung Cancer (MK-3475-407/KEYNOTE-407)
This is a study of carboplatin and paclitaxel or nano particle albumin-bound paclitaxel (nab-paclitaxel) with or without pembrolizumab (MK-3475, KEYTRUDA®) in adults with first line metastatic squamous non-small cell lung cancer…
- Trial name
- NCT02775435
- Testing
- Pembrolizumab, Paclitaxel, Nab-paclitaxel
- Volunteers
- 559 people
- Sponsor
- Merck Sharp & Dohme LLC
Advanced Solid Tumor, Cutaneous Tumor
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
This is a Phase 1, multicenter, open-label dose escalation study to determine the safety and tolerability of intratumoral (IT) injection of tolododekin alfa (ANK-101) in participants with advanced solid tumors who have progressed…
- Conditions
- Advanced Solid Tumor, Cutaneous Tumor, Subcutaneous Tumor, Malignant Solid Tumor
- Trial name
- ANCHOR (NCT06171750)
- Testing
- tolododekin alfa, Cemiplimab
- Where
- 5 sites in United States, Canada
- Volunteers
- 97 people
- Sponsor
- Ankyra Therapeutics, Inc
Nonsquamous Non-small Cell Lung Cancer
Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006)
The purpose of this study is to assess the safety and efficacy of pemetrexed + platinum chemotherapy + pembrolizumab (MK-3475) with or without lenvatinib (MK-7902/E7080) as first-line intervention in adults with metastatic…
- Trial name
- NCT03829319
- Testing
- Pembrolizumab, Carboplatin, Cisplatin
- Where
- 158 sites in United States, Argentina and 15 more
- Volunteers
- 761 people
- Sponsor
- Merck Sharp & Dohme LLC
Advanced Non Small Cell Lung Cancer, Advanced (Inoperable) Non Small Cell Lung Cancer
AZD9291 First Time In Patients Ascending Dose Study
This study will treat patients with advanced NSCLC who have already received at least one course of specific anti-cancer treatment but the tumour has started to re-grow following that treatment.
- Trial name
- AURA (NCT01802632)
- Testing
- AZD9291
- Where
- 45 sites in United States, Australia and 8 more
- Volunteers
- 603 people
- Sponsor
- AstraZeneca
Cancer, Cancer, Lung
A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors
The goal of this clinical trial is to test CPO301, a type of drug called an antibody drug conjugate in adult patients with advanced or metastatic solid tumors.
- Trial name
- NCT05948865
- Testing
- CPO301
- Where
- 14 sites in United States, Canada
- Volunteers
- 132 people
- Sponsor
- Conjupro Biotherapeutics, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.